Compare DSS & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSS | GTBP |
|---|---|---|
| Founded | 1984 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 2.6M |
| IPO Year | N/A | N/A |
| Metric | DSS | GTBP |
|---|---|---|
| Price | $0.97 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.8K | ★ 1.2M |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,046,000.00 | N/A |
| Revenue This Year | $14.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.53 | N/A |
| 52 Week Low | $0.72 | $0.54 |
| 52 Week High | $1.90 | $4.10 |
| Indicator | DSS | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 56.57 |
| Support Level | $0.98 | $0.63 |
| Resistance Level | $0.99 | $0.75 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 14.29 | 75.73 |
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.